We have shown that SH3BP2 downregulation regulates the viability of GIST cells with activating KIT mutations that are sensitive (GIST882) and resistant (GIST48) to imatinib treatment. The gene discussed is SH3BP2; the disease is gastrointestinal stromal tumor.